N

ovartis’ groundbreaking CAR-T cancer therapy is one big step closer to reaching patients.

A panel of outside experts convened by the FDA voted 10-0 Wednesday to recommend the approval of Novartis’ CAR-T therapy, called CTL019, for the treatment of children and young adults with advanced leukemia. The vote marks a pivotal milestone for this class of experimental treatment. The FDA is expected to make a final decision on approval by Oct. 3.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

    • Yes, CTL019 can work against any malignancy that expresses CD19, which would be any B cell malignancy such as ALL, CLL, and various B cell lymphomas. It also works against multiple myeloma, but they are not certain why it works. It either attacks a CD19+ precursor, or MM cells express CD19 briefly or at low levels and get killed off.

  • You should know the truth about CANCER. There are so many different therapies & drugs out there, far better to avoid Cancer. Spirit know what causes CANCER so people are not confused about it.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X